Last $184.50 CLP
Change Today +1.00 / 0.54%
Volume 9.9M
CFR On Other Exchanges
Sant. Comerc
As of 6:00 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

cfr pharmaceuticals sa (CFR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/11/14 - $185.00
52 Week Low
02/7/14 - $103.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CFR PHARMACEUTICALS SA (CFR)

Related News

No related news articles were found.

cfr pharmaceuticals sa (CFR) Related Businessweek News

No Related Businessweek News Found

cfr pharmaceuticals sa (CFR) Details

CFR Pharmaceuticals S.A. is engaged in the research, development, production, and sale of specialty generic medicines and complex injectables primarily in Latin America. It offers specialty pharma products comprising women’s health, neurology, psychiatry, general medicine, pneumology, otorhinolaryngology, allergies, cardiology, dermatology, ophthalmology, and generic products. The company also provides complex therapeutic drugs for the treatment of complex illnesses consisting sterile injectable products and lyophilized forms for anesthesia, infections, cardiology, and intensive care; and biological products, monoclonal antibodies, and treatments for dialysis, transplants, oncology, and rheumatology. In addition, it offers over-the-counter products, nutrition, food supplements, and homeopathic products. The company was founded in 1922 and is based in Providencia, Chile.

7,258 Employees
Last Reported Date: 05/29/14
Founded in 1922

cfr pharmaceuticals sa (CFR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cfr pharmaceuticals sa (CFR) Key Developments

CFR Pharmaceuticals S.A. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2014

CFR Pharmaceuticals S.A. reported consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net revenues of USD 181.6 million compared to USD 167.2 million a year ago. Profit before taxes was USD 33.0 million compared to USD 24.7 million a year ago. Profit attributable to owners of the parent company was USD 29.8 million compared to USD 19.6 million a year ago. Net cash flows from operating activities were USD 7.2 million compared to USD 9.5 million a year ago. Addition of PP&E was USD 1.9 million against USD 2.2 million for the same period a year ago. Addition of intangible assets was USD 1.2 million compared to USD 3.7 million a year ago. EBITDA was USD 35.9 million from USD 39.0 million a year ago. EBIT was USD 30.5 million compared to USD 33.1 million a year ago. Recurring EBITDA was USD 43.6 million against USD 40.0 million for the same period a year ago.

Abbott Laboratories, CFR Pharmaceuticals S.A. - M&A Call

To discuss definitive agreement to acquire CFR Pharmaceuticals

CFR Pharmaceuticals S.A. Presents at Bank of America Merrill Lynch - 2014 Emerging Markets Corporate Conference, May-28-2014

CFR Pharmaceuticals S.A. Presents at Bank of America Merrill Lynch - 2014 Emerging Markets Corporate Conference, May-28-2014 . Venue: Fontainebleau Miami Beach, 4441 Collins Avenue, Miami Beach, Florida, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFR:CI $184.50 CLP +1.00

CFR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CFR Industry Range
Price/Earnings 41.3x
Price/Sales 3.6x
Price/Book 4.6x
Price/Cash Flow 40.9x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CFR PHARMACEUTICALS SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at